Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07020221 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Verastem.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 295
- Enrollment target
- 12
- Study locations
NCT07020221 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that is actively recruiting participants, run by Verastem. The registered enrollment target is 295 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (55% lower). The trial reports 12 study locations across 12 states.
The verdict
NCT07020221, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Verastem.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 295 participants
- Enrollment target
- 12
- Study locations
Study Summary
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Conditions Studied
Interventions
- DRUG Cetuximab
- DRUG Gemcitabine
- DRUG VS-7375
- DRUG Carboplatin + Pemetrexed + Pembrolizumab
- DRUG Gemcitabine + Nab-paclitaxel
Study Locations (12)
California
- Cedars-Sinai Medical Center - Los Angeles
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- University of Michigan - Ann Arbor
Missouri
- Washington University School of Medicine - St Louis
New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone - New York
Pennsylvania
- Univ of Pennsylvania, Abramson Cancer Center - Philadelphia
Tennessee
- SCRI Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2025-06-24 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07020221
The ClinicalTrials.gov registry entry for NCT07020221 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 295 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (55% lower). The listed sponsor is Verastem, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Cetuximab is the first listed.
NCT07020221 reports 12 study locations spanning 12 distinct geographic areas - top geographies include California, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07020221 about?
NCT07020221 is a clinical study titled "A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors". This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
What is the current status of trial NCT07020221?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 295 participants. The study started on 2025-06-24. Estimated completion is 2028-12.
What conditions does trial NCT07020221 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor, Adult, G12D Mutated KRAS.
What interventions are being tested in trial NCT07020221?
The interventions under investigation include: Cetuximab (DRUG), Gemcitabine (DRUG), VS-7375 (DRUG), Carboplatin + Pemetrexed + Pembrolizumab (DRUG), Gemcitabine + Nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT07020221?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07020221 being conducted?
This trial has 12 study locations across California, Maryland, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.